New COVID Variant BA.2.3 Spreads to 29 States

A new COVID-19 Omicron subvariant, BA.3.2, has been detected across the United States , with the Centers for Disease Control and Prevention (CDC) reporting its identification in 29 U.S. states and Puerto Rico. Health officials said the variant contains many spike-protein mutations, a feature that typically draws close scientific attention because the spike is central to how the virus enters cells and how immune defenses recognize it.

Public health experts said there is currently no evidence that BA.3.2 causes more severe illness than other recently circulating variants. The World Health Organization (WHO) has placed BA.3.2 in its “variant under monitoring” category, which is below classifications used for variants considered higher risk. That status reflects ongoing tracking rather than a determination that the variant is driving worse outcomes.

Dr. Jake Scott, a Stanford professor and infectious disease expert, said BA.3.2 has not shown a sustained growth advantage compared with other variants spreading at the same time. He also said it has not been linked to increased hospitalizations or deaths. In the U.S., BA.3.2 represents a low share of the COVID-19 infections that have been analyzed, according to the information cited by experts.

Outside the United States, BA.3.2 has reached a substantial portion of sequenced cases in parts of Europe, according to the account provided, but there has not been a clear signal of worse clinical outcomes. Experts said this international pattern is being watched closely because shifts in variant prevalence can affect public health planning, even when severity does not appear to change.

Current vaccines are expected to remain effective against BA.3.2, with experts saying protection against severe disease, hospitalization, and death is maintained. Based on the evidence described, specialists advised that neither public health authorities nor the general public need to change current behaviors specifically in response to BA.3.2 at this time.

2, officials and experts said, so that emerging data can inform future vaccine adjustments if needed. 2 appearing overrepresented in pediatric samples in some countries; however, they cautioned that it is too early to draw firm conclusions without clearer information on underlying infection rates and how testing and sequencing practices may be shaping the data.